O

OSIVAX

40 employees

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

Basic info

Industry

biotechnology research

Sectors

Biotechnology

Immuno-oncology

immunology

biotechnology

antigens

universal

Health Care

Influenza

Clinical Trials

cellular immune response

Infectious diseases

CD8 T-cell

covid

vaccine

Date founded

2017

Funding rounds raised

Total raised

$17M

from 5 investors over 5 rounds

O

OSIVAX raised $1M on March 28, 2023

Investors: Bill & Melinda Gates Foundation

O

OSIVAX raised $17M on July 8, 2020

Investors: Anaxago

O

OSIVAX raised $9M on July 10, 2019

Investors: Anaxago and -

O

OSIVAX raised $3M on June 15, 2017